The basics of ketogenic diet: works of Shaffer and Wilder & Winter

It is interesting that while the ketogenic diet becomes well researched as a method for improving energy metabolism during quite a few medical conditions and the number of original research articles as well as reviews grow currently approaching 15,000, only 19 out of all of them cite the original work, which in fact is the basis of the diet. >>> Read more

The ketogenic diet is no longer considered a strictly anti-epileptic diet: its suggested and tested applications includes a broad spectrum of disorders of energy metabolism. The ketogenic ratio formula used in clinics for calculating the ketogenic diet composition was offered by Wilder and Winter in 1922 (1). They argued that the levels of ketogenic substances depend on the ratio between fatty acids and glucose of the metabolizing foods. The ratio when ketogenesis is initiated they called the threshold of ketogenesis: “When the proportion of acetoacetic acid to glucose in such mixtures was that of 1 (or possibly 2) molecules of acetoacetic acid to 1 of glucose, the former substance was completely oxidized. When the proportion of glucose was less, a considerable fraction of acetoacetic acid escaped oxidation.”

Shaffer (2, 3) calculated the number of molecules of ketogenic substrates corresponding to the number of molecules of glucose and concluded that the maximal ratio compatible with the oxidation of the ketogeniec compounds was reached when a ratio of of ketogenic molecules to the number of glucose molecules was 1: 1. He subsequently considered that each glucose molecule is ketolytic for 2 molecules of acetoacetic acid, a 2:l ratio.

Wilder and Winter, 1922 included in their formula the following measurements obtained in clinical settings:

1) basal metabolism for 24 hour periods plus 10 per cent for the specific dynamic action of food and 10 per cent for movements;

2) the calories from the protein metabolism assessed by nitrogen excretion;

3) the calories from fat metabolism taken as the sum of the calories of protein and carbohydrate combined subtracted from the total calories of the day.

The values for carbohydrate and fat are used in the calculation of the ratio between the ketogenic molecules and the glucose molecules (2, 3).

“Under the conditions of these experiments, provided these assumptions are tenable, the ratio between the ketogenic and the glucose molecules at which a clinically significant ketosis appears has a value of at least 2: 1. A ratio of this value implies that every molecule of glucose is ketolytic for 2 molecules of acetoacetic acid.”

References

  1. Wilder R., Winter M. Thew threshold of ketogenesis. J. Biol. Chem. 1922 52: 393-401.
  2. Shaffer, P. A., Antiketogenesis. I. An in vitro analogy, J. Biol.Chem., 1921, xlvii, 433.
  3. Shaffer, P. A., Antiketogenesis. II. The ketogenic antiketogenic balance in man, J. Biol. Chem., 1921, xlvii, 449.

 

 

 

Alzheimer’s disease and a long-standing exposure to glucose in the Western diet

 

Chronic exposure to glucose due to the traditional Western diet impairs neuronal function and causes apoptosis (programmed neuronal death), concluded Drs Seneff & Wainwright (UK) and Mascitelli (Italy). Their reasoning was roughly the following:

The amyloid-beta peptide (AB) in Alzheimer’s disease (AD) plaques so far seen as a hallmark of this disease, in fact may be an early attempt of protection from its development.  AB switches neuronal metabolism from glycolysis-based to the use of other substrates, e.g., lactate and ketone bodies. This is a very important adjustment in the AD case since there’s an insulin resistance in the AD brain indicating an inadequate ability to utilize glucose. Moreover, the levels of advanced glycation end-products (harmful in any case) are increased in AD. The damage they induce interferes with delivery of fats and cholesterol to astrocytes, and consequently to neurons. This is important because for smooth communication between neurons, sufficient levels of fat and cholesterol is required and the AD CSF is deficient in both. Synthesis of AB is increased when lipid supply is deficient. In the condition of this deficiency, there’s an increase in synthesis of excitatory neurotransmitter glutamate leading to oxidative damage and toxic overexcitability.

The good news is, wrote the authors, a simple dietary change towards lower carbohydrate intake and higher fats intake, may be efficiently protective against AD.

Source:

European Journal of Internal Medicine 22 (2011) 134–140

Neuroprotective effects of vitamins C and E against epilepsy-induced neuronal death

Epilepsy is thought to be associated with oxidative stress, which play its role in the seizures-induced neuronal death (1, 2). On the other hand, the brain, due to a high content of polyunsaturated fatty acids, is an easy target for the peroxidation. Luckily, it has neuroprotective systems such as superoxide dismutase, catalase, glutathione peroxidase and reduced glutathione (3, 4).

Exogenous antioxidants like vitamin E and C, can inhibit the neuronal damage provoced by lipid peroxidation during seizures and prevent the increase in brain free fatty acid levels, suggesting that the protection may be mediated by, for example, increase of hippocampal catalase activity (5). Vitamin C significantly decreased the lipid peroxidation after seizures induced by cholinergic agonist pilocarpine supporting the idea of interaction of the C and E vitamins with catalase activity to produce neuronal protection amd to decrease the lipid peroxidation level (6).

When oxidative damage accumulates over  years, it may account for the increased incidence of neurodegenerative diseases in aged populations. The mechanisms of neuronal degeneration in these cases remain unknown and this is a major obstacle in the development of effective therapies targeting the causes of the diseases.

Sources

  1. Neurosci Lett 420 (2007), pp. 76–79
  2. Neurosci Lett 291 (2000), pp. 179–182
  3. Cell signaling and neurotoxic events. In: L.W. Chang, Editor, Principles of Neurotoxicology, Marcel Dekker, New York (1994), pp. 475–493
  4. Neurosci Lett 8 (2007), pp. 76–79
  5. Epilepsy Res 46 (2001), pp. 121–128
  6. Pharmac Biochem & Behavior, Volume 89, Issue 1, March 2008, Pages 1-5

Glucose versus lactate in immature brain slices

Related Q&A: Y Ben-Ari writes that ‘Zilberter and Bregestovski and colleagues’ dealt with ‘ketone body metabolites’. What does ketone body metabolite mean? ”

About this post

1. These quotes were first used by Elly Strammer at F1000.com. After she agreed to remove her post from there, she contacted us suggesting that we use the quotes. We thank Elly for her contribution and for further commenting at the Naturally Selected

2. We received many questions regarding this post, quite a few of them concerned the formatting, which was not helping to clearly understand the issue. Because of that, we updated the post making sure to visually indicate quotes belonging to the arguing sides (according to F1000.comNow, remarks related to comments concerning the works of Y. Zilberter et al. are marked as  and remarks by Y. Ben-Ari are marked as 

 ”We demonstrate that in the neonatal brain, Em [membrane potential] and EGABA [reversal potential of GABA-induced anionic currents] strongly depend on composition of the energy substrate pool. Complementing glucose with ketone bodies, pyruvate or lactate resulted in a significant hyperpolarization of both Em and EGABA, and induced a radical shift in the mode of GABAergic synaptic transmission towards network inhibition.” (1)

“The main conclusions of our work are that the inhibitory effect of L-lactate on GDPs is not mediated by mitochondrial energy metabolism, and that glucose at its standard 10 mM concentration is an adequate energy substrate for neonatal neurons in vitro.” (2)

 ”We show that in the presence of glucose, lactate is effectively utilized as an energy substrate, causing an augmentation of oxidative metabolism. Moreover, in the absence of glucose lactate is fully capable of maintaining synaptic function. Therefore, during network activity in neonatal slices, lactate can be an efficient energy substrate capable of sustaining and enhancing aerobic energy metabolism.” (3)

“Lactate is not an efficient replacement for glucose and, as in vivo glucose is always kept at 4-5mM in the brain even in conditions of severe stress.” (4 a)

“The fact is, in the extracellular fluid (ECF) in the brain, glucose concentration is between 1.9 mM and 0.59 while lactate concentration is between 5.1 mM and 0.78 mM (for review, see [9 in this post]). The question arises: why 10 mM glucose in standard ACSF is adequate but 10 mM lactate is not.” (5)

“Clearly, the suggestions of Zilberter and colleagues rely on wrong assumptions and results that have not been reproduced.” (4 a)

“The effect of weak acids on GABA reversal potential and GDP generation was initially described for 4-5 mM concentrations of BHB [ketone body beta-hydroxybutyrate] (Rheims et al. 2009 ), lactate and pyruvate (Holmgren et al. 2010), and was later confirmed by independent research groups for similar concentrations of pyruvate (Tyzio et al. 2011), lactate and propionate (Ruusuvuori et al. 2010).” (6)

“From a clinical perspective, it is interesting to stress that relying on their observations on the positive actions of lactate on metabolism, Zilberter and colleagues have suggested that administration of lactate may be “a novel therapeutic tool to cure Parkinson, Alzheimer, Leigh syndrome and epilepsies” (4a)

 From Brain Fuels: This quotation is taken out of context. The exact piece from (9) reads: “… a growing body of evidence shows that metabolic stress caused by impaired energy homeostasis is a common feature of neurodegenerative disorders (NDDs) such as Alzheimer disease, Leigh syndrome, epilepsy, dementia, multiple sclerosis, neuropathies or ataxias [88] and [89]. We speculate that endogenous ES such as lactate, BHB and pyruvate or their combinations can be efficient in treatingNDD, and would address the cause rather than symptoms. Indeed, the neuroprotective effects of pyruvate have been repeatedly demonstrated in cases of brain ischemia, hypoglycemia, hemorragia, stroke and kainate-inducedepileptic brain damage[90], [91], [92]and [93]. Further research into mechanisms of the effects of ES on fundamental neuronal properties might allow more rapid progress in preventing and managing NDDs.

The comment made on 29 Jul 2011 (4 b) quoted this paragraph with the references removed thus attributing the text solely to (9).

“Considering the compelling and well-known clinical observation that high lactate level is a classical sign of neuron suffering and severe conditions that require rapid intervention, this suggestion is, to say the least, astonishing.” (4 a)

“The bulk of the evidence suggests that lactate is an important intermediary in numerous metabolic processes, a particularly mobile fuel for aerobic metabolism, and perhaps a mediator of redox state among various compartments both within and between cells. Lactate can no longer be considered the usual suspect for metabolic ‘crimes’, but is instead a central player in cellular, regional and whole body metabolism… we might term the period from the 1930s to approximately the early 1970s the dead-end waste product era.” (7)

” It is curious that Dr Zilberter and colleagues refer to metabolism but have never reported measuring it.” (4 b)

“…Ivanov et al. (2011) simultaneously recorded oxygen tension, NAD(P)H fluorescence transients and local field potentials during electrical stimulation of the hippocampal Schaffer collateral pathway in neonatal brain tissue slices from mice. From the very beginning, the authors took great care to ensure both viability and functionality of their preparations. They convincingly demonstrated that surprisingly high superfusion rates with standard artificial cerebrospinal fluid (ACSF) in the slice chamber are required to ensure adequate oxygenation and complete electrical function in blood-free tissue slices. An important implication of this methodological tour de force is that under many previously reported experiments the requirements for viability may been met while the functionality may have been compromised.” (8)

References

  1. Holmgren, C. D., Mukhtarov, M., Malkov, A. E., Popova, I. Y., Bregestovski, P., and Zilberter, Y. (2010). Energy substrate availability as a determinant of neuronal resting potential, GABA signaling and spontaneous network activity in the neonatal cortex in vitro. J. Neurochem. 112, 900–912.
  2. Ruusuvuori E et al. (2010). Spontaneous network events driven by depolarizing GABA action in neonatal hippocampal slices are not attributable to deficient mitochondrial energy metabolism. J Neurosci. Nov 17; 30(46):15638-42
  3. Ivanov A, Mukhtarov M, Bregestovski P and Zilberter Y (2011) Lactate effectively covers energy demands during neuronal network activity in neonatal hippocampal slices. Front. Neuroenerg. 3:2.
  4. Ben-Ari Y.  a) Faculty of 1000, 06 Jan 2011, evaluation,  b) 29 Jul 2011, comment.
  5. Zilberter Y. Faculty of 1000, 19 May 2011 and July 14 2011, comments.
  6. Khakhalin A (May 18, 2011). Questioning the depolarizing effects of GABA during early brain development. J Neurophysiol doi: 0.1152/jn.00293.2011.
  7. Mendel I. Faculty of 1000, 04 Jun 2011, comment (Currently the comment is removed).
  8. Kasischke K (2011) Lactate fuels the neonatal brain. Front. Neuroenerg. 3:4. doi: 10.3389/fnene.2011.00004
  9. Zilberter Y, Zilberter T, Bregestovski P. (2010) Neuronal activity in vitro and the in vivo reality: the role of energy homeostasis. Trends PharmacolSci 31:394–401.

What can be done to fight off Alzheimer’s disease?

Q&A and FAQ (archived) :: Ongoing Q&A :: Neuroscience Q&A and FAQ

Question
I’ve read on WebMD that there’s no evidence that anything can be done to fight off Alzheimer’s disease. But I also read the opposite opinions. What is yours? – Donna

Answer
Dear Donna,

You probably mean the following conclusion cited by WebMD:

“There is currently no evidence considered to be of even moderate scientific quality supporting the association of any modifiable factor (nutritional supplements, herbal preparations, dietary factors, prescription or nonprescription drugs, social or economic factors, medical conditions, toxins, environmental exposures) with reduced risk of Alzheimer’s disease,” concludes the report, issued by a National Institutes of Health consensus panel on Alzheimer’s prevention.”

I am surprised that they haven’t mentioned exercise, for which, in my humble opinion, a solid body of evidence exists and the caffein research, for which intricate mechanisms are being researched. Also, quite a few harmful influences such as hydrogen peroxide, glutamate, zinc, and copper/cysteine were convincingly reported. I added caffein effects on another neurodegenerative disease, the Parkinson’s but I know of similar studies in Alzheimer’s.

Walking away from dementia

Coffee, tea, and chocolate can help to avoid Parkinson’s disease

Pyruvate protects neurons against A-beta peptides characteristic for Alzheimer’s
Tanya Zilberter

Sweet and sour recipes for the brain. 1. “Sweet slices are fine”?

Is glucose the absolutely exclusive fuel for the brain? In popular articles, you might always read that yes, it is.

Meanwhile, in special scientific literature the role of quite a few energy carriers including ketone bodies (mostly beta-hydroxybutirate, BHB), lactate, and pyruvate was unquestioned for decades. Recently, a series of three research reports published in the Journal of Neuroscience (Tyzio et al., 2011, Ruusuvuori et al., 2010 and Kirmse et al., 2010) arrived at the conclusion contradicting to the well known fact about brain energy metabolism in neonates. It seemed indisputable that in the neonatal brain, the use of glucose as an energy substrate is limited due to immaturity of the mechanisms of glucose utilization but the articles in question shed doubts on it. Why is it important to sort out these conflicting research results?

I already wrote about the importance of energy substrates other than glucose for the immature brain and the consequence of ignoring this role in experiments on neonatal brain slices discussing the results of Rheims et al., 2009 and Holmgren et al., 2010.

In 2010, at the meeting of the Society for Neuroscience in San Diego, CA, a poster has been presented announcing in its title: “BHB does not alter GABA signals in neonatal slices: sweet slices are fine, no need to alter conventional ACSF“. Neither poster nor its abstract (Picardo et al., 2010) contained methodical details and they remained unknown until 2011 when an article in the Journal of Neuroscience was published (Tyzio et al., 2011). It became possible to compare the differences in methods, which has been done in due time and published in the Frontiers in Neuroenergetics (Ivanov et al., 2011) — see parts 2-4.

Important is, that Ivanov et al. showed that in immature brain slices, glucose rendered less efficient energy carrier than lactate, BHB, and pyruvate.  Judged by the hallmarks of energy metabolism – oxygen utilization and nicotinamide adenine dinucleotide phosphate or NAD(P)H, neuronal activity robustness was higher in the presence of lactate alone or combined with glucose than with glucose alone. The authors concluded: “We show that in the presence of glucose, lactate is effectively utilized as an energy substrate, causing an  augmentation of oxidative metabolism. Moreover, in the absence of glucose lactate is fully capable of maintaining synaptic function. Therefore, during network activity in neonatal slices, lactate can be  an efficient energy substrate capable of sustaining and enhancing aerobic energy metabolism.”

References

  1. Garcia, A.J., 3rd, Putnam, R.W., and Dean, J.B. (2010). Hyperbaric hyperoxia and normobaric reoxygenation increase excitability and activate oxygen-induced potentiation in CA1 hippocampal neurons. J Appl Physiol 109, 804-819.
  2. Hajos, N., Ellender, T.J., Zemankovics, R., Mann, E.O., Exley, R., Cragg, S.J., Freund, T.F., and Paulsen, O. (2009). Maintaining network activity in submerged hippocampal slices: importance of oxygen supply. Eur J Neurosci 29, 319-327.
  3. Holmgren CD, Mukhtarov M, Malkov AE, Popova IY, Bregestovski P, Zilberter Y (2010) Energy substrate availability as a determinant of neuronal resting potential,GABAsignaling and spontaneous network activity in the neonatal cortex in vitro. J Neurochem 112:900 –912.
  4. Ivanov A, Mukhtarov M, Bregestovski P and Zilberter Y (2011). Lactate effectively covers energy demands during neuronal network activity in neonatal hippocampal slices. Front. Neuroenerg. 3:2.
  5. Kirmse K, Witte OW, Holthoff K. (2010). GABA Depolarizes Immature Neocortical Neurons in the Presence of the Ketone Body β-Hydroxybutyrate. J Neuroscience, 24; 30(47): 16002-16007
  6. Lehninger, A.L. (2005). “Oxydative phosphorylation and photophosphorylation,” in Principles of biochemistry, eds. D.L. Nelson & M.M. Cox. Forth ed: W. H. Freeman), 690-740.
  7. Rheims S, Holmgren CD, Chazal G, Mulder J, Harkany T, Zilberter T, Zilberter Y (2009) GABA action in immature neocortical neurons directly depends on the availability of ketone bodies. J Neurochem 110: 1330–1338.
  8. Schurr, A., and Payne, R.S. (2007). Lactate, not pyruvate, is neuronal aerobic glycolysis end product: an in vitro electrophysiological study. Neuroscience 147, 613-619.
  9. Tyzio, R., Allene, C., Nardou, R., Picardo, M.A., Yamamoto, S., Sivakumaran, S., Caiati, M.D., Rheims, S., Minlebaev, M., Milh, M., Ferre, P., Khazipov, R., Romette, J.L., Lorquin, J., Cossart, R., Khalilov, I., Nehlig, A., Cherubini, E., and Ben-Ari, Y. (2011). Depolarizing actions of GABA in immature neurons depend neither on ketone bodies nor on pyruvate. J Neurosci 31, 34-45.

Neuroprotective effects of Coenzyme Q10

Related: Is Q10 a fitness-enhancing or an anti-aging supplement in the long run?

“Several clinical trials of CoQ10 have been performed in Parkinson’s disease and atypical Parkinson’s syndromes, Huntington’s disease, Alzheimer disease, Friedreich’s ataxia, and amyotrophic lateral sclerosis, with equivocal findings. CoQ10 is widely available in multiple formulations and is very well tolerated with minimal adverse effects, making it an attractive potential therapy.”
Meredith Spindler, M Flint Beal, and Claire Henchcliffe. Coenzyme Q10 effects in neurodegenerative disease. Neuropsychiatr Dis Treat. 2009; 5: 597–610
“There is ample evidence showing involvement of mitochondrial dysfunction in the pathogenesis of neurodegenerative disorders, therefore, one would predict that agents that alleviate mitochondrial dysfunction could be beneficial and exert neuroprotective effects. Several bioenergetic agents that improve mitochondrial function including creatine, coenzyme Q10 (CoQ10), nicotinamide, riboflavin and lipoic acid are being tested for their neuroprotective efficacy in neurodegenerative disorders. Among them, creatine and CoQ10 are in clinical trials for PD, HD and AD.”
Rajnish K. Chaturvedi and M. Flint Beal. Mitochondrial approaches for neuroprotection. Ann N Y Acad Sci. 2008 December; 1147: 395–412
“…combination therapy using CoQ10 and creatine may be useful in the treatment of neurodegenerative diseases such as Parkinson’s disease and HD.”
Lichuan Yang  et al., Combination therapy with Coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson’s and Huntington’s Diseases. J Neurochemistry, 109, 5, 1427–1439, 2009
“…a synthetic analog of CoQ10, idebenone, has been investigated in clinical trials for its ability to inhibit lipid peroxidation. Although several smaller studies reported beneficial effects on memory and attention after several months of treatment, a larger study reported no effect in slowing disease progression.”
Magali Dumont, M. Flint Beal. Neuroprotective strategies involving ROS in Alzheimer disease. Free Radical Biology and Medicine, 2011, online ahead of print
“These data demonstrate that in addition to reducing intracellular deposition of A-beta, CoQ10 can also reduce plaque pathology. Our study further supports the use
of CoQ10 as a therapeutic candidate for AD.”
Xifei Yang et al., Coenzyme Q10 Reduces β-Amyloid Plaque in an APP/PS1
Transgenic Mouse Model of Alzheimer’s Disease. Mol Neurosci (2010) 41:110–113
Abbreviations

PD: Parkinson’s disease;
HD: Huntington’s disease;
AD: Alzheimer’s disease;
A-beta – beta-Amyloid peptide

Brain and iodine deficiency in children and adults

Related:

Food sources of iodine

Selected nutrients in foods

Iodine plays an important role in the synthesis of thyroid hormones, which regulate the metabolic processes in the brain. Iodine deficiency affecting thyroid hormones during this critical periods of brain development result in hypothyroidism and brain damage. Iodine consumption in the geographic locations known to be deficient areas can be below those needed for the brain normal development and both children and adults in these areas can be at risk of brain disorders and mental retardation (Thyroid 2000;10:871–87).

In Toscani, in 6–10 year old children with mild iodine deficiency (64 micrograms/day), the slowing of reaction in movement tasks was observed (Endocrinol Invest 1995;18:57–62) as well as low visual-motor performances, motor skill and perception. These children had low development quotients and IQ (Iodine and the brain. New York: Plenum Press, 1989: 1–379). The IQ in otherwise normal children deficient in iodine is shifted towards low values (Bull World Health Organ 1986;64:547–51; J Nutr, 1999;129:980–7).

Severe endemic iodine deficiency such as in New Guinea, China, Indonesia, and Thailand causes the clinical picture of cretinism with dominant neurological pathologies (Thyroid 1993;3:59–69; Eur J Endocrinol 1997;137:349–55). It has been shown experimentally that the most detrimental is the combination of iodine and selenium deficiencies. In the rat fetuses in such condition, experiments showed the developmental failure of the central nervous system (Nutritional factors involved in the goitrogenic action of cassava. Ottawa: International Development Research Centre, 1982: 74–83).

“Endemic cretinism is now included in the spectrum of the effects of iodine deficiency in a population termed the ‘iodine deficiency disorders (IDDs)’, which also includes a wide range of lesser degrees of cognitive defect that can be prevented by the correction of iodine deficiency. Iodine deficiency is now recognised by the World Health Organization (WHO) as the most common preventable cause of brain damage with in excess of 2 billion at risk from 130 countries.” — Z-P. Chen & B.S. Hetzel (2010). Cretinism revisited. Best Practice & Research Clinical Endocrinology & Metabolism, 24:1, 39-50

The eight mechanisms of anti-Alzheimer’s effects of curcumin

Related: Resveratrol and curcumin, plant’s own weapons that protect the brain

1. Curcumin is a better antioxidant than alpha-tocopherol and can protect blood vessel cells from oxidative stress caused by Amyloid beta peptide (Abeta), the main constituent of amyloid plaques in the brains of Alzheimer’s disease (AD) patients. Interestingly, with low-dose curcumin, but not with high-dose curcumin the plaque occurrence was decreased by up to 50%.

2. Curcumin significantly lowered levels of oxidized proteins, which content is elevated in the brains of mice model of AD.

3. Curcumin inhibits the formation of fibrillar Abeta (fAbeta) and destabilized already formed fAbeta.

4. In animal models of AD, curcumin prevented cognitive deficits presumably by binding the redox-active metals Fe and Cu.

5. Curcumin decreased Abeta formation. When fed to aged mice with advanced amyloid accumulation, curcumin directly binds small beta-amyloid and blocks fibril formation.

6. Beta-amyloid peptide can form a peroxidase playing a major role in the pathologies of AD. Curcumin inhibits this peroxidase.

7. Curcumin enhances the phagocytosis and Abeta removal by macrophages, the process that is impaired in patients with AD.

8. Curcumin crosses the blood–brain barrier, disrupts existing plaques and partially restores damaged neurones in annimal AD model leading to a significant reversal of structural neuronal damage.

Source

B.B. Aggarwal, K.B. Harikumar. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. The International Journal of Biochemistry & Cell Biology 41 (2009) 40–59

Cannabinoids, marijuana – health effects

Question: Hi. Please, before you claim this as outside of your expertise I would really appreciate your answer even if it is only a little information, you can send it to my email privately at too if you wish. So, I was wondering, what does marijuana do to our bodies and brains? How dangerous can it be?

I’m only asking because i smoked for 2 years then stopped for 3, and now I am doing it for a few weeks, not for recreational reasons though. And when I did it a few days ago my heart was pounding like crazy, I felt like I was going to die and I was thinking some crazy thoughts, and so I’m just trying to make sure i’ll be safe if I continue for the next few weeks?

I’m 19 and male. Thank you.

Answer: Dear Josh,

I’m listing the major known negative reactions caused by marijuana. Since I know neither the purpose of your return to marijuana nor your overall health condition, you must draw your own conclusions. Please don’t hesitate asking me any further questions especially if you find my reply too technical.

The plant Cannabis sativa has been used for or medical and religious purposes for at least over 4000 years and has been globally adopted for recreational use for the past 50 years. It’s been estimated that 166 million adults aged 15–64 years currently use cannabis. The psychoactive chemical of cannabis is Δ-9-tetrahydrocannabinol (THC). The deadly dose of THC is between 15 g and 70 g — much higher than that can be smoked by even a heavy user.

The most common acute negative reactions are frequent in beginning users. They are: anxiety, panic reactions including tachycardia (fast heart beat), and psychotic symptoms. Chronic users can suffer from memory deficits, motor performance impairment; as a result, cannabis users had higher rates of hospital admission for injury from all causes although alcohol intake has greater impact: driving after having taken cannabis increases the risk of vehicle crashes 2–3 times compared with 6–15 times under the influence of alcohol.

Other adverse effects include decreased levels of testosterone and increased rates of birth defects in babies born to mothers taken cannabis during pregnancy.

The lifetime risk of dependence in cannabis users is about 9% comparing with 32% for nicotine, 23% for heroin, 17% for cocaine, 15% for alcohol, and 11% for stimulant users.

Cannabis smoke contains many of the same carcinogens as does tobacco smoke so it’s no surprise that case–control study of hospital-diagnosed lung cancer and community controls indicated an increased incidence of lung cancer in cannabis users even after adjustment for cigarette smoking.

Cannabis use changes brain functions that can be detected by modern methods like positron emission tomography, and electroencephalography. Among most reproducible effects of cannabis withdrawal are: lower brain blood flow in certain regions of brain  cortex,  less activity in brain regions involved in memory and attention and changes in cannabinoid receptor activity in the hippocampus, prefrontal cortex, and cerebellum.

Tanya Zilberter

Source

W Hall, L Degenhardt. Adverse health effects of non-medical cannabis use. Lancet 2009; 374: 1383–91

Older Posts » To leave a comment or question click here